FindTrial
Sign In

Comparing Routine Care, Citrus Flavonoid Tablets, and Citrus Flavonoid Tablets Plus Maiguan Fukang Tablets for Leg Swelling After Knee Replacement

Safety and Efficacy of Citrus Flavonoid Tablets Alone or in Combination With Maiguan Fukang Tablets for Lower-Extremity Swelling After Primary Total Knee Arthroplasty: A Randomized, Assessor-Blinded, Usual-Care-Controlled, Three-Arm Parallel-Group Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600128936
Enrollment
Unknown
Registered
2026-07-28
Start date
2026-07-28
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Degenerative knee joint diseases like knee osteoarthritis

Interventions

Usual-care group:Standardized perioperative care
Citrus flavonoid plus Maiguan Fukang group:Citrus flavonoid tablets plus Maiguan Fukang tablets
Citrus flavonoid tablets group:Citrus flavonoid tablets

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age 18 to 80, planning to undergo primary unilateral total knee replacement (mainly for knee osteoarthritis and other degenerative diseases). 2. American Society of Anesthesiologists (ASA) physical status I, II, or III. 3. The patient has signed a written informed consent.ments.

Exclusion criteria

Exclusion criteria: 1. Significant swelling in the lower limbs before surgery or a clear diagnosis of moderate to severe chronic venous insufficiency/lymphedema; 2. Significantly elevated inflammatory markers before surgery (like CRP >10 mg/L or IL-6 >15 pg/mL) or active infection; 3. Hemoglobin 1.5 times the normal upper limit, etc.); 4. Severe peripheral arterial disease (like ankle-brachial index 2 times the normal upper limit, serum creatinine >2 times the normal upper limit); 8. Allergy to citrus flavonoid tablets or related flavonoid drugs, or a clear allergic reaction after previous use; 9. Women who are pregnant or breastfeeding, or planning pregnancy during the study period; 10. Those judged by the researcher as unsuitable to participate.

Design outcomes

Primary

MeasureTime frame
Percentage change in circumference at the superior pole of the patella at 72 hours after surgery;Knee function and health-related quality-of-life scores;—

Secondary

MeasureTime frame
Visual analogue scale scores for pain at rest and during movement;Cumulative postoperative opioid consumption;Postoperative bleeding-related outcomes;Knee range of motion;Coagulation parameters and lower-extremity venous thrombosis assessment;Percentage changes and postoperative trajectories of lower-extremity circumference at different anatomical levels;Serum inflammatory marker levels;Incidence of adverse events and serious adverse events;—

Countries

China

Contacts

Public ContactSi Haibo

West China Hospital of Sichuan University

sihaibo@wchscu.cn+86 28 8542 2570

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026